Literature DB >> 21855670

Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?

Laurence S Lim1, Chui Ming Gemmy Cheung1, Paul Mitchell2, Tien Y Wong3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21855670     DOI： 10.1016/j.ajo.2011.05.040

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN： 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  16 in total

1.  Age-related macular degeneration and long-term risk of stroke subtypes.

Authors:  M Kamran Ikram; Paul Mitchell; Ronald Klein; A Rickey Sharrett; David J Couper; Tien Y Wong
Journal:  Stroke       Date:  2012-04-24       Impact factor: 7.914

2.  Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis.

Authors:  Joel Hanhart; Doron S Comaneshter; Yossi Freier-Dror; Shlomo Vinker
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-10       Impact factor: 3.117

3.  Ischaemic colitis associated with intravitreal administration of aflibercept: A first case report.

Authors:  Benjamin Batteux; Valérie Gras; Yanis Mahboud; Sophie Liabeuf; Youssef Bennis; Kamel Masmoudi
Journal:  Br J Clin Pharmacol       Date:  2019-02-01       Impact factor: 4.335

4.  mTOR inhibition as a novel gene therapeutic strategy for diabetic retinopathy.

Authors:  Steven Hyun Seung Lee; Joo Yong Lee; Jun-Sub Choi; Hee Jong Kim; Jin Kim; Seho Cha; Kyoung Jin Lee; Ha-Na Woo; Keerang Park; Heuiran Lee
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

Review 5.  Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.

Authors:  K Ghasemi Falavarjani; Q D Nguyen
Journal:  Eye (Lond)       Date:  2013-05-31       Impact factor: 3.775

Review 6.  Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.

Authors:  Lorenzo Moja; Ersilia Lucenteforte; Koren H Kwag; Vittorio Bertele; Annalisa Campomori; Usha Chakravarthy; Roberto D'Amico; Kay Dickersin; Laurent Kodjikian; Kristina Lindsley; Yoon Loke; Maureen Maguire; Daniel F Martin; Alessandro Mugelli; Bernd Mühlbauer; Isabel Püntmann; Barnaby Reeves; Chris Rogers; Christine Schmucker; Manju L Subramanian; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2014-09-15

Review 7.  Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy.

Authors:  Selwyn M Prea; Elsa C Chan; Gregory J Dusting; Algis J Vingrys; Bang V Bui; Guei-Sheung Liu
Journal:  J Ophthalmol       Date:  2015-03-03       Impact factor: 1.909

Review 8.  Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application.

Authors:  Yan Zhang; Qian Han; Yusha Ru; Qiyu Bo; Rui Hua Wei
Journal:  Drug Des Devel Ther       Date:  2015-07-02       Impact factor: 4.162

9.  Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.

Authors:  Frank S Ong; Jane Z Kuo; Wei-Chi Wu; Ching-Yu Cheng; Wendell-Lamar B Blackwell; Brian L Taylor; Wayne W Grody; Jerome I Rotter; Chi-Chun Lai; Tien Y Wong
Journal:  J Pers Med       Date:  2013

10.  Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration.

Authors:  Katarzyna Michalska-Małecka; Adam Kabiesz; Malgorzata W Kimsa; Barbara Strzałka-Mrozik; Maria Formińska-Kapuścik; Malgorzata Nita; Urszula Mazurek
Journal:  Clin Interv Aging       Date:  2016-03-24       Impact factor: 4.458
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.